JP2003513911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003513911A5 JP2003513911A5 JP2001536130A JP2001536130A JP2003513911A5 JP 2003513911 A5 JP2003513911 A5 JP 2003513911A5 JP 2001536130 A JP2001536130 A JP 2001536130A JP 2001536130 A JP2001536130 A JP 2001536130A JP 2003513911 A5 JP2003513911 A5 JP 2003513911A5
- Authority
- JP
- Japan
- Prior art keywords
- cisplatin
- encapsulated
- human
- animal body
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 36
- 229960004316 cisplatin Drugs 0.000 description 36
- 238000000034 method Methods 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 239000000693 micelle Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- -1 phosphatidylglycerol lipid Chemical class 0.000 description 7
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 6
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000799 fusogenic effect Effects 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- CNAHGDCINXNHER-JKSUJKDBSA-N 1,2-dihexanoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCC(=O)OC[C@@H](OC(=O)CCCCC)COP(O)(=O)OC[C@@H](O)CO CNAHGDCINXNHER-JKSUJKDBSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 229960004413 flucytosine Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/434,345 US6511676B1 (en) | 1999-11-05 | 1999-11-05 | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US09/434,345 | 1999-11-05 | ||
| PCT/US2000/029723 WO2001034130A1 (en) | 1999-11-05 | 2000-10-27 | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011247471A Division JP5711099B2 (ja) | 1999-11-05 | 2011-11-11 | シスプラチン及び他の薬剤又はリポソーム中に封入された遺伝子を用いてのヒト癌のための療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513911A JP2003513911A (ja) | 2003-04-15 |
| JP2003513911A5 true JP2003513911A5 (https=) | 2007-02-15 |
Family
ID=23723848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001536130A Withdrawn JP2003513911A (ja) | 1999-11-05 | 2000-10-27 | シスプラチン及び他の薬剤又はリポソーム中に封入された遺伝子を用いてのヒト癌のための療法 |
| JP2011247471A Expired - Fee Related JP5711099B2 (ja) | 1999-11-05 | 2011-11-11 | シスプラチン及び他の薬剤又はリポソーム中に封入された遺伝子を用いてのヒト癌のための療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011247471A Expired - Fee Related JP5711099B2 (ja) | 1999-11-05 | 2011-11-11 | シスプラチン及び他の薬剤又はリポソーム中に封入された遺伝子を用いてのヒト癌のための療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6511676B1 (https=) |
| EP (1) | EP1156789B9 (https=) |
| JP (2) | JP2003513911A (https=) |
| CN (1) | CN100562311C (https=) |
| AT (1) | ATE321541T1 (https=) |
| AU (1) | AU777151B2 (https=) |
| CA (1) | CA2358948C (https=) |
| CY (1) | CY1105628T1 (https=) |
| DE (1) | DE60027039T2 (https=) |
| DK (1) | DK1156789T3 (https=) |
| ES (1) | ES2261251T3 (https=) |
| GR (1) | GR1004168B (https=) |
| PT (1) | PT1156789E (https=) |
| TW (1) | TWI259770B (https=) |
| WO (1) | WO2001034130A1 (https=) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE397066T1 (de) * | 1993-10-27 | 2008-06-15 | Univ Columbia | Methode zur bildung einer subtrahierten cdna bank und ihre verwendung |
| US5710137A (en) | 1996-08-16 | 1998-01-20 | The Trustees Of Columbia University In The City Of New York | Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| CA2396431A1 (en) * | 1999-11-29 | 2001-05-31 | Advanced Research And Technology Institute, Inc. | Sustained percutaneous delivery of a biologically active substance |
| US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| EP1301213B1 (en) * | 2000-07-21 | 2017-01-18 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
| CA2430897C (en) * | 2000-12-07 | 2010-11-16 | Universiteit Utrecht Holding B.V. | Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders |
| US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| JP2005502653A (ja) * | 2001-08-20 | 2005-01-27 | トランセーヴ・インコーポレーテッド | 肺ガンの治療方法 |
| CA2457148A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
| WO2003028696A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Compositions for delivery of drug combinations |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| WO2003075889A1 (en) * | 2002-03-05 | 2003-09-18 | Transave, Inc. | An inhalation system for prevention and treatment of intracellular infections |
| US20030180348A1 (en) * | 2002-03-22 | 2003-09-25 | Levinson R. Saul | Transcellular drug delivery system |
| US20090060992A1 (en) * | 2002-05-08 | 2009-03-05 | University Of Central Florida Research Foundation, Inc., | Preparation of magneto-vesicles with DOPE/DDAB layers |
| US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
| US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
| JP2006502233A (ja) * | 2002-08-02 | 2006-01-19 | トランセーブ，インク． | 白金凝集物およびその製造方法 |
| EP1393720A1 (en) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| EP1581236B1 (en) * | 2002-10-29 | 2013-10-16 | Insmed Incorporated | Sustained release of antiinfectives |
| JP4874547B2 (ja) * | 2002-11-26 | 2012-02-15 | ギリアード サイエンシーズ， インコーポレイテッド | 勾配によるリポソームへの薬物充填方法 |
| US7670604B2 (en) | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| US7413851B2 (en) * | 2002-12-13 | 2008-08-19 | Aurelium Biopharma, Inc. | Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| US7550256B2 (en) * | 2002-12-13 | 2009-06-23 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| AU2003300676A1 (en) * | 2003-01-03 | 2004-07-29 | Aurelium Biopharma Inc. | Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| WO2004080819A2 (en) * | 2003-03-14 | 2004-09-23 | Aurelium Biopharma Inc. | Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
| EP1643971A2 (en) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| CA2535584A1 (en) * | 2003-08-13 | 2005-02-24 | University Of South Florida | Platinum complexes for the treatment of tumors |
| CA2538729A1 (en) * | 2003-09-12 | 2005-03-31 | Avi Biopharma, Inc. | Compound and method for treating androgen-independent prostate cancer |
| US20050095283A1 (en) * | 2003-09-16 | 2005-05-05 | Aphios Corporation | Compositions and methods for topically treating diseases |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| EP1687017B1 (en) | 2003-10-24 | 2013-03-06 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| CN100471493C (zh) * | 2003-12-17 | 2009-03-25 | 梅比欧法姆股份有限公司 | 含有奥沙利铂的脂质体制剂 |
| CA2558676C (en) | 2004-03-03 | 2019-04-16 | Essentia Biosystems, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US8784881B2 (en) * | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
| WO2005089448A2 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
| CA2928387A1 (en) | 2004-05-03 | 2005-11-17 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| CN101001633A (zh) * | 2004-05-21 | 2007-07-18 | 特兰萨夫公司 | 肺病和肺病前期病症的治疗 |
| US20060246124A1 (en) * | 2004-11-08 | 2006-11-02 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
| SG160357A1 (en) * | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US20060283742A1 (en) * | 2005-06-16 | 2006-12-21 | Canel Lightning Co. Ltd. | Multi-lamp display packaging for lamps with collapsible lampshades |
| US20080088046A1 (en) * | 2006-10-13 | 2008-04-17 | Steffen Panzner | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| CA2891996A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| WO2007056263A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| US20070190181A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously |
| US9107824B2 (en) * | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| US20090304766A1 (en) * | 2005-11-30 | 2009-12-10 | Lawrence Mayer | Localized delivery of drug combinations |
| HUE029994T2 (en) | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| GR20060100144A (el) * | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| DE102006040647A1 (de) * | 2006-08-30 | 2008-03-13 | Robert Bosch Gmbh | Handwerkzeugmaschine |
| NZ578164A (en) | 2007-01-16 | 2011-12-22 | Musc Found For Res Dev | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| WO2008137717A1 (en) * | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| US20100215582A1 (en) * | 2007-05-14 | 2010-08-26 | Konica Minolta Holdings, Inc. | Liposome and method for producing liposome |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| CA2700808C (en) | 2007-09-27 | 2017-11-14 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| EP2209420A4 (en) | 2007-10-09 | 2014-01-22 | Univ St Louis | PARTICULARS FOR IMAGING |
| US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| KR100890317B1 (ko) | 2008-05-08 | 2009-03-26 | 고려대학교 산학협력단 | 플라티늄 항암제 조성물 및 제제 |
| ES2524699T3 (es) * | 2008-06-05 | 2014-12-11 | Immunovaccine Technologies Inc. | Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba |
| WO2009156706A1 (en) * | 2008-06-27 | 2009-12-30 | University Of Strathclyde | Pulmonary drug delivery with vesicles comprising non-ionic surfactants |
| US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| TWI437001B (zh) * | 2009-04-06 | 2014-05-11 | Food Industry Res & Dev Inst | 氮雜芬酮（ａｚａｐｈｉｌｏｎｅ）化合物於調節核荷爾蒙受體活性之用途 |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| CN102038640B (zh) * | 2009-10-26 | 2013-11-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法 |
| JP2013514999A (ja) | 2009-12-17 | 2013-05-02 | ワシントン・ユニバーシティ | 抗血栓性ナノ粒子 |
| US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
| AU2011239414A1 (en) * | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
| BR112013005202B1 (pt) * | 2010-09-02 | 2021-07-27 | The Scripps Research Institute | Lipídeo legumaína-alvo, composição de nanopartículas de legumaína-alvo e usos dos mesmos |
| PL220281B1 (pl) | 2011-09-23 | 2015-09-30 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA |
| JP6240077B2 (ja) | 2011-10-06 | 2017-11-29 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
| CN102525928B (zh) * | 2012-02-20 | 2014-04-02 | 中国药科大学 | 一种顺铂长循环脂质体及其制备方法 |
| MX369828B (es) | 2012-05-21 | 2019-11-22 | Insmed Inc | Sistemas para tratar infecciones pulmonares. |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| SG11201501147WA (en) * | 2012-08-13 | 2015-04-29 | Regulon Inc | Methods for treatment of cancer using lipoplatin |
| CN121606602A (zh) | 2012-09-04 | 2026-03-06 | 埃莱森制药股份有限公司 | 用顺铂脂质复合物预防癌症的肺部复发 |
| CN104884065B (zh) | 2012-09-21 | 2019-01-01 | 强烈治疗剂公司 | 治疗癌症的方法 |
| CA2925687A1 (en) * | 2012-09-27 | 2014-04-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
| US10113151B2 (en) | 2012-10-29 | 2018-10-30 | The Regents Of The University Of California | Composition of viral vectors in lecithin liposomes, preparation method and treatment methods |
| RU2018135921A (ru) | 2012-11-29 | 2019-02-05 | Инсмед Инкорпорейтед | Стабилизированные составы ванкомицина |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| MX385425B (es) | 2015-08-21 | 2025-03-18 | Ipsen Biopharm Ltd | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. |
| JP6924431B2 (ja) * | 2015-10-13 | 2021-08-25 | 株式会社ケーナインラボ | ヒトを除く哺乳動物への薬剤の投与方法 |
| MX382522B (es) | 2015-10-16 | 2025-03-13 | Ipsen Biopharm Ltd | Composiciones farmaceuticas estabilizantes de camptotecina. |
| FI127460B (en) | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| US10987353B2 (en) | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
| FR3051674B1 (fr) * | 2016-05-31 | 2019-11-08 | Universite De Bourgogne | Lipoproteines chargees en complexes de platine pour le traitement du cancer |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| US20190231690A1 (en) * | 2017-11-08 | 2019-08-01 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
| CN108042490B (zh) * | 2018-01-10 | 2020-09-15 | 华中科技大学 | 纳米载药系统、其制备方法、药物组合物及在治疗癌症中的应用 |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| JP7197106B2 (ja) * | 2018-04-27 | 2022-12-27 | 国立大学法人北海道大学 | 脂質ナノ粒子 |
| WO2019213398A1 (en) | 2018-05-02 | 2019-11-07 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| US11246945B2 (en) | 2019-06-07 | 2022-02-15 | National Defense Medical Center | Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer |
| JP2023521400A (ja) * | 2020-04-09 | 2023-05-24 | デファイメッド | 医療デバイス用の膜 |
| CN118127042B (zh) * | 2024-03-18 | 2024-10-22 | 安阳工学院 | GhBC1基因及其相关生物材料在调控植物油脂积累中的应用 |
| CN118873677B (zh) * | 2024-07-08 | 2025-12-30 | 北京化工大学 | 病原体相关分子模式表面修饰的抗肿瘤脂质体纳米载药系统及其制备方法与应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2862498A (en) * | 1957-06-14 | 1958-12-02 | Don J Weekes | Endotracheal tube |
| US3554673A (en) * | 1969-01-31 | 1971-01-12 | Sage Instr Inc | Syringe pump |
| US3683908A (en) * | 1969-10-20 | 1972-08-15 | Tantrimudalige Anthony Don Mic | Apparatus for sealing the oesophagus and providing artificial respiration |
| US4104357A (en) * | 1973-01-10 | 1978-08-01 | Monster Molding, Inc. | Method of rotational molding about plural axes at low rotational speeds |
| US3931822A (en) * | 1974-02-26 | 1976-01-13 | Marici Frank N | Automatic alternating cuff endo tracheal tube inflator |
| US4231365A (en) * | 1978-01-30 | 1980-11-04 | Scarberry Eugene N | Emergency resuscitation apparatus |
| DE2816203C2 (de) * | 1978-04-14 | 1982-07-15 | Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart | Schalteinrichtung für ein elektrisch gesteuertes Brennstoff-Einspritzsystem bei Brennkraftmaschinen |
| GB2111394B (en) * | 1981-12-16 | 1985-09-11 | Archibald Ian Jeremy Brain | Artificial airway device |
| US4553540A (en) * | 1983-08-16 | 1985-11-19 | Straith Richard E | Airway |
| US4793327A (en) * | 1986-01-21 | 1988-12-27 | Frankel Alfred R | Device for opening a patient's airway during automatic intubation of the trachea |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5203320A (en) * | 1987-03-24 | 1993-04-20 | Augustine Medical, Inc. | Tracheal intubation guide |
| US4832020A (en) * | 1987-03-24 | 1989-05-23 | Augustine Scott D | Tracheal intubation guide |
| US5042469A (en) * | 1987-03-24 | 1991-08-27 | Augustine Medical, Inc. | Tracheal intubation guide |
| US4872483A (en) * | 1987-12-31 | 1989-10-10 | International Medical Products, Inc. | Conveniently hand held self-contained electronic manometer and pressure modulating device |
| US4953547A (en) * | 1989-01-26 | 1990-09-04 | Poole Jr Samuel E | Drug administering endotracheal respiration systems |
| GB2229367A (en) * | 1989-03-22 | 1990-09-26 | Archibald Ian Jeremy Brain | Artificial airway device |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| DE69026820T2 (de) * | 1989-03-31 | 1996-11-28 | Univ California | Zubereitung von liposomen- und lipid-komplexzusammensetzungen |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5038766A (en) * | 1989-11-08 | 1991-08-13 | Parker Jeffrey D | Blind orolaryngeal and oroesophageal guiding and aiming device |
| US5174283A (en) * | 1989-11-08 | 1992-12-29 | Parker Jeffrey D | Blind orolaryngeal and oroesophageal guiding and aiming device |
| IS1685B (is) | 1990-12-11 | 1998-02-24 | Bracco International B.V. | Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum |
| GB9102821D0 (en) * | 1991-02-11 | 1991-03-27 | Brain Archibald Ian Jeremy | An intubating laryngeal mask airway |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5339808A (en) * | 1991-04-02 | 1994-08-23 | Don Michael T Anthony | Endotracheal-esophageal intubation devices |
| US5235973A (en) * | 1991-05-15 | 1993-08-17 | Gary Levinson | Tracheal tube cuff inflation control and monitoring system |
| GB9119703D0 (en) * | 1991-09-14 | 1991-10-30 | Dingley John | Medico-surgical device |
| MX9301163A (es) * | 1992-03-05 | 1994-07-29 | Brain Archibald Ian Jeremy | Mascara laringea y metodo para su fabricacion. |
| GB9204754D0 (en) * | 1992-03-05 | 1992-04-15 | Brain Archibald Ian Jeremy | Mould for manufacture of a laryngeal mask |
| US5249571A (en) * | 1992-05-21 | 1993-10-05 | Brain Archibald Ian Jeremy | Laryngeal clamp airway |
| CN1079385A (zh) * | 1992-06-01 | 1993-12-15 | 丛繁滋 | 抗癌药物脂质体的制备方法 |
| US5297547A (en) * | 1992-07-30 | 1994-03-29 | Brain Archibald Ian Jeremy | Laryngeal mask construction |
| US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5355879A (en) * | 1992-09-28 | 1994-10-18 | Brain Archibald Ian Jeremy | Laryngeal-mask construction |
| US5443063A (en) * | 1993-08-31 | 1995-08-22 | The Johns Hopkins University | Cuffed oro-pharyngeal airway |
| US5599301A (en) * | 1993-11-22 | 1997-02-04 | Advanced Cardiovascular Systems, Inc. | Motor control system for an automatic catheter inflation system |
| GB2285765B (en) * | 1994-01-12 | 1997-10-29 | Archibald Ian Jeremy Brain | Forming tool for use with a laryngeal mask |
| US5529582A (en) * | 1994-02-01 | 1996-06-25 | Fukuhara; Tomio | Apparatus for inserting laryngeal mask |
| US5582167A (en) * | 1994-03-02 | 1996-12-10 | Thomas Jefferson University | Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure |
| JP3782123B2 (ja) * | 1994-05-31 | 2006-06-07 | 住友ベークライト株式会社 | 咽腔用エアウエイ |
| US5569219A (en) * | 1994-09-13 | 1996-10-29 | Hakki; A-Hamid | Collapsible catheter |
| GB9422224D0 (en) * | 1994-11-03 | 1994-12-21 | Brain Archibald Ian Jeremy | A laryngeal mask airway device modified to detect and/or stimulate mescle or nerve activity |
| US5477851A (en) * | 1995-01-26 | 1995-12-26 | Callaghan; Eric B. | Laryngeal mask assembly and method for removing same |
| GB9504657D0 (en) * | 1995-03-08 | 1995-04-26 | Neil Michael J O | An improved artificial airway device |
| GB9505134D0 (en) * | 1995-03-14 | 1995-05-03 | Smiths Industries Plc | Laryngeal mask airways |
| GB9505399D0 (en) * | 1995-03-17 | 1995-05-03 | Smiths Industries Plc | Medico-surgical devices |
| US5908777A (en) | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| GB9513860D0 (en) * | 1995-07-07 | 1995-09-06 | Smiths Industries Plc | Securing devices |
| MY115052A (en) * | 1995-10-03 | 2003-03-31 | Archibald Ian Jeremy Brain | Laryngeal mask airway incorporating an epiglottic elevating mechanism |
| US5791341A (en) * | 1995-12-19 | 1998-08-11 | Bullard; James Roger | Oropharyngeal stent with laryngeal aditus shield and nasal airway with laryngeal aditus shield |
| US5694929A (en) * | 1996-02-26 | 1997-12-09 | Christopher; Kent L. | Method and apparatus for ventilation/oxygenation during guided insertion of an endotracheal tube |
| US5623921A (en) * | 1996-04-10 | 1997-04-29 | Kinsinger; J. William | Laryngeal mask airway and method for its use |
| US5894060A (en) | 1996-06-28 | 1999-04-13 | Boulikas; Teni | Cloning method for trapping human origins of replication |
| US5682880A (en) * | 1996-07-26 | 1997-11-04 | Brain; Archibald Ian Jeremy | Laryngeal-mask airway with guide element, stiffener, and fiberoptic access |
| CA2263455C (en) | 1996-08-23 | 2002-10-29 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
| US5738094A (en) * | 1996-08-30 | 1998-04-14 | Hoftman; Moshe | Anesthesia/respirator mask with reduced nasal section enclosure and inflatable cuff |
| GB9619432D0 (en) * | 1996-09-18 | 1996-10-30 | Smiths Industries Plc | Laryngeal mask assemblies |
| GB2318297B (en) * | 1996-10-16 | 2000-04-12 | Smiths Industries Plc | A tracheal shield assembly |
| GB9622880D0 (en) * | 1996-11-02 | 1997-01-08 | Smiths Industries Plc | Laryngeal mask airways and thier manufacture |
| GB9624029D0 (en) * | 1996-11-19 | 1997-01-08 | Smiths Industries Ltd | Laryngeal mask airways and their manufacture |
| US5843475A (en) * | 1996-12-06 | 1998-12-01 | Board Of Regents, The University Of Texas System | Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes |
| GB9702337D0 (en) * | 1997-02-05 | 1997-03-26 | Smiths Industries Plc | Laryngeal mask airways and their manufacture |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| GB9705585D0 (en) * | 1997-03-18 | 1997-05-07 | Smiths Industries Plc | Laryngeal mask assemlies |
| US5743254A (en) * | 1997-03-18 | 1998-04-28 | Parker Medical Limited Partnership | Orotracheal intubation guide |
| GB9705586D0 (en) * | 1997-03-18 | 1997-05-07 | Smiths Industries Plc | Laryngeal mask assemblies |
| GB9705537D0 (en) * | 1997-03-18 | 1997-05-07 | Smiths Industries Plc | Laryngeal mask assemblies |
| US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US5937860A (en) * | 1997-04-10 | 1999-08-17 | Cook; Daniel J. | Laryngeal mask |
| GB9708568D0 (en) * | 1997-04-29 | 1997-06-18 | Smiths Industries Ltd | Cuffed medico-surgical tubes |
| US5988167A (en) * | 1997-05-02 | 1999-11-23 | Kamen; Jack M. | Foam cuff for laryngeal mask airway |
| US5850832A (en) * | 1997-06-23 | 1998-12-22 | Chu; Kyo Y. | Laryngeal mask airway insertion guide |
| GB9721840D0 (en) * | 1997-10-16 | 1997-12-17 | Smiths Industries Plc | Laryngeal mask assemblies |
| US6003510A (en) * | 1997-12-04 | 1999-12-21 | Anunta; Boonchuay | Hand tool for introducing a laryngeal mask |
| GB9817537D0 (en) * | 1998-08-13 | 1998-10-07 | Brain Archibald Ian Jeremy | A laryngear mask airway with mutually independant laterally-placed ultra-flexible eastric access/discharge and airway tubes |
| US6705318B1 (en) * | 1999-04-09 | 2004-03-16 | Archibald I. J. Brain | Disposable LMA |
| US6390093B1 (en) * | 1999-04-14 | 2002-05-21 | Vital Signs, Inc. | Artificial airway device and method of its use |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US6427688B1 (en) * | 2000-02-01 | 2002-08-06 | Dura Pharmaceuticals, Icn. | Dry powder inhaler |
| GB2383755B (en) * | 2002-01-04 | 2004-02-25 | Future Top Medical Environment | Obturator for use with a laryngeal mask airway |
-
1999
- 1999-11-05 US US09/434,345 patent/US6511676B1/en not_active Expired - Lifetime
-
2000
- 2000-10-27 JP JP2001536130A patent/JP2003513911A/ja not_active Withdrawn
- 2000-10-27 CN CNB008046611A patent/CN100562311C/zh not_active Expired - Fee Related
- 2000-10-27 DE DE60027039T patent/DE60027039T2/de not_active Expired - Lifetime
- 2000-10-27 ES ES00972379T patent/ES2261251T3/es not_active Expired - Lifetime
- 2000-10-27 AT AT00972379T patent/ATE321541T1/de active
- 2000-10-27 EP EP00972379A patent/EP1156789B9/en not_active Expired - Lifetime
- 2000-10-27 AU AU11048/01A patent/AU777151B2/en not_active Ceased
- 2000-10-27 WO PCT/US2000/029723 patent/WO2001034130A1/en not_active Ceased
- 2000-10-27 CA CA002358948A patent/CA2358948C/en not_active Expired - Fee Related
- 2000-10-27 DK DK00972379T patent/DK1156789T3/da active
- 2000-10-27 PT PT00972379T patent/PT1156789E/pt unknown
- 2000-11-03 GR GR20000100384A patent/GR1004168B/el not_active IP Right Cessation
- 2000-11-03 TW TW089123244A patent/TWI259770B/zh not_active IP Right Cessation
-
2003
- 2003-01-23 US US10/350,470 patent/US7393478B2/en not_active Expired - Fee Related
-
2006
- 2006-06-28 CY CY20061100880T patent/CY1105628T1/el unknown
-
2008
- 2008-06-05 US US12/133,634 patent/US20090280164A1/en not_active Abandoned
-
2011
- 2011-11-11 JP JP2011247471A patent/JP5711099B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003513911A5 (https=) | ||
| CA2358948A1 (en) | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes | |
| Guevara et al. | Advances in lipid nanoparticles for mRNA-based cancer immunotherapy | |
| JP5122474B2 (ja) | 両性リポソーム製剤 | |
| CN102300556B (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| WO1995024201A1 (en) | Liposome preparation | |
| EP2382994A1 (en) | Ligand targeted nanocapsules for the delivery of RNAi and other agents | |
| Zheng et al. | Engineered non-viral gene vectors for combination cancer therapy: a review | |
| KR102769095B1 (ko) | 면역유도용 고분자 나노입자 조성물 및 그 제조방법 | |
| Mohammad | Key considerations in formulation development for gene therapy products | |
| WO2006102800A1 (en) | Nano-micellar preparation of anthracycline antitumor antibiotics wrapped by the polyethylene glycols derivative of phosphatide | |
| KR20240083166A (ko) | 폐를 표적장기로 하는 생분해성 지질나노입자 약물 전달 제형 및 이의 활용 | |
| JP4881327B2 (ja) | 抗腫瘍活性物質のリポソーム製剤 | |
| Nie et al. | Nonviral vector system for cancer immunogene therapy | |
| Baradaran et al. | A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy | |
| KR20220149400A (ko) | 이황화 결합을 갖는 양이온성 지질을 사용하여 약물을 전달하기 위한 나노입자 조성물 및 그 제조방법 | |
| CN112566627A (zh) | 用于递送病毒的高分子纳米粒子组合物及其制造方法 | |
| KR102402620B1 (ko) | 약물 전달을 위한 고밀도 지단백 모방 고형 지질 나노입자 및 이의 용도 | |
| Zarei et al. | Preparation and assessment of gingerol-loaded nanoliposomes and their effect on breast cancer cell lines (MCF-7) | |
| JP5817053B2 (ja) | 腫瘍特異性を有するリポソーム | |
| Aminu | Nanovesicles for drug codelivery | |
| CN114746124A (zh) | 包含活性剂沉淀物的递送系统复合物和使用方法 | |
| Chen et al. | Nanovehicles for delivery of antigens and adjuvants as cancer nanovaccines | |
| JP6404034B2 (ja) | 核酸を内封してなる中性又はアニオン性リポソーム及びその製造方法。 | |
| Bhambere et al. | Novel drug delivery systems in HIV/AIDS and associated complications |